A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK(®)) lowering cardiovascular disease risk

CONTEXT: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk. OBJECTIVE: To evaluate the cost and effectiveness of LopiGLIK(®) (LOPI) in lowering LDL-C and CVD risk. DESIGN: Single bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Manfrin, Andrea, Trimarco, Valentina, Manzi, Maria Virginia, Rozza, Francesco, Izzo, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181120/
https://www.ncbi.nlm.nih.gov/pubmed/30349338
http://dx.doi.org/10.2147/CEOR.S172838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181120/
https://www.ncbi.nlm.nih.gov/pubmed/30349338
http://dx.doi.org/10.2147/CEOR.S172838

Ejemplares similares